Sameer Kumar

Artificial Intelligence | Stock Investor| LLM Consultant

[Sameer Kumar @kumar_same65576]

#MAXVOLT

[Satish Patnaik @patnaiksatish84]

Maxvolt Energy
-----------------
Small steps....

Source - Linkedin

[Sameer Kumar @kumar_same65576]

@amurfalcon1 But their inventory days and receivables increased. Any reason for this?

[Sameer Kumar @kumar_same65576]

@amurfalcon1 CCTV has sector tailwinds.Both CPPLUS and Prizor are growing.But OSEL is in different sector.

[Sameer Kumar @kumar_same65576]

@REDBOXINDIA Nothing will change.
Anthropic will gain at the end.And this news came when India AI summit happened in India.Until we r more on R&D difficult to compete.

[Sameer Kumar @kumar_same65576]

@Sky16akash Indeed.

[Sameer Kumar @kumar_same65576]

Oriana Power – Key Takeaways from FY26 concall

1. Asset monetization planned for FY26 was delayed due to regulatory and external factors.Transaction now expected to close in FY27.
2. Management indicated that the deferred monetization was expected to contribute a significant portion of FY26 profits and should reflect in upcoming results if completed.
3. Core business operations remain strong, with management emphasizing that the earnings miss was largely due to timing rather than operational weakness.
4. BESS (Battery Energy Storage Systems) is emerging as a major growth driver and is expected to contribute 30–40% of revenues by FY27.
5. Company is transitioning from a pure Solar EPC player to an integrated clean-energy platform covering:
Solar EPC
IPP
BESS
Floating Solar
Green Hydrogen
6. Strong project pipeline and execution visibility continue across solar and storage segments.
7. Asset recycling will be a recurring strategy: develop assets → monetize at premium valuations → reinvest capital into new projects.
8. Green Hydrogen remains a strategic focus area, with meaningful revenue contribution expected from FY28 onwards.
9. AI-driven systems are being deployed across engineering, procurement, construction, O&M, finance, and compliance to improve efficiency and scalability.
10. Management remains confident about long-term growth despite challenges such as module price volatility, currency fluctuations, grid constraints, and regulatory changes.

[Sameer Kumar @kumar_same65576]

Venus Remedies.

[TruthCapital @ramesh_vd]

#venusremedies

Is Venus Remedies a boring 15–20% compounder quietly doing hospital supply rounds — or a deeply misunderstood asymmetric bet hiding behind a pharma label nobody bothers to read? 🧵

The business
Venus Remedies is not your typical pharma company grinding out generic tablets for retail chemists. It operates in a niche that most investors walk past: sterile injectable formulations for hospital ICUs — antibiotics that fight drug-resistant superbugs, chemotherapy injectables, and critical care drugs that can only be delivered intravenously in a controlled clinical setting.

For nearly a decade the company struggled — good science, poor commercialisation, heavy debt. Then management made two pivots that changed everything: they stopped selling complex molecules directly, instead signing manufacturing alliances with Cipla, Zydus, and Intas who already owned hospital relationships. And they cleared every rupee of debt from operating cash flow. Today Venus runs a debt-free balance sheet with ₹250+ Cr in unencumbered cash — while its sterile lines run at near-full capacity.

The moat — especially the IP layer
Two-layer moat.
The outer wall: 1,000+ global Marketing Authorisations(license to sell medicines) tied to specific plants, non-transferable, each taking 18–36 months to secure. Any competitor replicating Venus's export footprint needs a decade and hundreds of crores just for paperwork.

The inner wall — the one the market keeps mispricing — lives inside the Venus Medicine Research Centre (VMRC). A DSIR-recognised in-house lab generating 135+ global patents across the US, EU, and India. The core breakthrough: proprietary Antibiotic Adjuvant Entities — molecules that don't just treat infections, they disarm the bacterial resistance mechanism itself. The flagship Elores shields antibiotics from the beta-lactamase and carbapenemase enzymes bacteria use to neutralise them.

Management — why trust them

Two reasons: tested under pressure, and kept their word.

Dr Manu Chaudhary (Joint MD, PhD structural biology) personally anchors the 135+ patent portfolio — a promoter-scientist who built the core moat. Pawan Chaudhary (MD) architected the commercial pivot. Saransh Chaudhary (next-gen, CEO Venusiac) now drives global out-licensing of Elores.

Promoters hold 41.76% equity with zero shares pledged. When debt was heavy and commercialisation was stalling, management did not dilute equity, did not diversify — they paid down every rupee from operations. FY26 net profit: ₹102.78 Cr, up 127% YoY. Under-promise, over-deliver.

Current numbers and EPS trajectory
FY26 actuals: Sales ₹769.6 Cr · EBITDA margin 18.5% · PAT ₹102.8 Cr · EPS ₹76.9 · ROIC 21.8% · CFO ₹155 Cr — cash conversion 1.5× reported profit.

Base-case model at 15–18% guided revenue growth: FY27E EPS ₹91.7 · FY28E EPS ₹128.7. At CMP ₹1,610, that is 12.5× forward P/E on FY28E — priced as if it is still the debt-heavy generic manufacturer of five years ago.

The asymmetric bet — four levers and why now

Most estimates only capture revenue growth. The real asymmetry is what happens when product mix shifts toward high-margin, IP-protected molecules.

1. Mix shift: generic → proprietary IP drugs — the highest-probability lever and the most direct EPS driver. Venus sells a blend of commodity generics (gross margin ~28–30%) and proprietary patented formulations like Elores (gross margin ~45–50%+). As Elores scales deeper into hospital formularies, every 5% revenue mix shift adds ~150–200 bps EBITDA margin. On just 1.33 Cr shares, each 100 bps margin expansion = ~₹5–6 EPS uplift. If EBITDA exits at 26–28% instead of 22.5%, FY28E EPS reaches ₹155–170 — not ₹128.

2. Global Elores out-licensing milestones — Venus already received a ₹11 Cr milestone payment from one AMR licensing deal. Each EU or US agreement adds upfront fees plus multi-year royalties — zero incremental capex. Two or three deals could add ₹15–25 Cr PAT annually, translating to +₹11–19 EPS purely from licensing income.

3. AMR becomes a global policy emergency — WHO, G7, and EU have flagged antimicrobial resistance as a tier-1 crisis. Fast-track procurement frameworks for proven AMR therapies are being legislated now. Venus is one of the very few companies globally with commercially validated, patented, adjuvant-based AMR solutions already in 60+ countries — a potential strategic acquisition target for Big Pharma missing this platform entirely.

4. Plerixafor oncology inflection — entry into the $65B → $105B chemo injectable market via GCC and EU hospital formularies. EU-GMP manufacturing and regulatory filings are already in place. Adoption is a matter of when, not whether.

⚡ Why now — five reasons the window is open today
→ Balance sheet inflection just happened. The debt paydown that unlocks all future optionality was completed in FY26. You are evaluating this in the first year of a clean, self-funding capital structure

→ Capacity expansion is being commissioned now. The ₹65 Cr Baddi lyophilisation line — which raises the revenue ceiling from ₹850 Cr to ₹1,150 Cr — goes live in Q2 FY27. The earnings impact will show up in the next 2–3 quarters.

→ Mix shift is at its earliest visible stage. EBITDA expanded from 12% to 18.5% in a single year as patented molecules grew faster than generics. The inflection has started . At 22–28% EBITDA, this is a completely different earnings machine.

→ Global AMR policy is accelerating. The EU's AMR Action Plan and the US PASTEUR Act are moving from discussion to legislation in 2025–26. Governments are creating guaranteed procurement frameworks for validated AMR drugs — and Elores is one of the very few that qualifies today.

→ Valuation has not caught up (or has it ??). At 12.5× FY28E on a debt-free, 21%+ ROIC, IP-protected business with an expanding moat — the stock is priced for a generic compounder's destiny, not a specialty pharma platform's (it may be totally wrong to interpret this way).

Venus Remedies is an IP-protected, debt-free, founder-scientist-run specialty pharma company at 12.5× FY28E earnings. The base case already works. The mix-shift toward proprietary molecules is already happening and unpriced. The licensing optionality, AMR tailwind, and oncology expansion sit on top as free options. The window is open because the balance sheet cleared last year and the capacity expansion fires next quarter.

Is the market still seeing a debt-laden generic injectable manufacturer from five years ago — or has it simply not looked closely enough at what is quietly being built inside?

[Not investment advice, DYOR]

[Shiladitya @shiladitya4u]

Sakar Healthcare
There are quite a few companies in the small & microcap pharma space which I like and Sakar healthcare is one of my favorites.

The investment thesis for Sakar is very simple -

It's a play on their oncology scale up, mainly exports.
Sakar has an extremely robust pipeline of oncology products, and all the levers are in place for super fast scale up.
FY26 revenue - 251 CR, Oncology = 38% = 95 Cr, Non-oncology = 156 Cr (62%)
Q4FY26 revenue - 71 Cr, Oncology = 31 Cr (46%) , Nononcology = 40 Cr (54%)
Within Oncology, it is almost entirely domestic.

Now, herein comes the kicker.
While domestic Oncology is poised to grow at 10-15%, management expects Exports revenue from Oncology to match the domestic oncology business in FY27 (remember exports oncology revenue is almost 0 in FY26). So, overall oncology portfolio is poised to double in FY27 !!

Sakar has already built capacity to scale up to 1000 Cr revenue, that's 4X FY26 revenue

Once the revenue starts increasing, margins are going to increase due to operating leverage (current utilization is only 30%) Also, oncology has a higher margin profile than non-oncology business. So, that will also boost margins.

Management has given a guidance of 40% CAGR for next few years.
Valuations are very reasonable if you consider FY27 and FY28 earnings. ICICI estimates PAT of 50 Cr for FY27 and 82 Cr for FY28, which means stock is trading at PE of 35 and 21 respectively.

Personally, I think FY28 PAT can be close to 100 crores, which means the stock is trading at 17-18 times FY28 EPS. For such a high growth oncology focused pharma company with a long runway, I feel this offers good risk:reward.

Disc: invested & biased, no recos. Do your own research.

[Sameer Kumar @kumar_same65576]

@samisosa1234 Flex Fuel will be the future.

[Sameer Kumar @kumar_same65576]

@ayushmarda07 Do they have investor ppt?I am not finding this.

[Sameer Kumar @kumar_same65576]

@shubham1492 Indeed @shubham1492 bhai.

[Sameer Kumar @kumar_same65576]

@Vismaya9999 @Srav1i Happy birthday @Vismaya9999 .

[Sameer Kumar @kumar_same65576]

@shubham1492 This is really useful.Excellent data. Please share the query.

[Sameer Kumar @kumar_same65576]

#oriana
Message from the management

[Sameer Kumar @kumar_same65576]

#MAXVOLT

[Aishvik @Aishvik361675]

Maxvolt Energy Industries Ltd: Powering India’s Unregistered EV & Aggressive Shift into Circular Battery Economies https://t.co/CFhjHtTcFR

[Sameer Kumar @kumar_same65576]

Sakar and Zydus has an agreement to supply Oncology products in the GCC and other markets.
#sakar

[Sameer Kumar @kumar_same65576]

@shome_rajarshi @amurfalcon1 Thanks for sharing the details @shome_rajarshi bhai.
They are adding their store addition in every month and this year again 100 more stores.Expecting good growth in this year.

[Sameer Kumar @kumar_same65576]

@piyush_trades Good information. Thanks for sharing .

[Sameer Kumar @kumar_same65576]

Result season is almost going to over. Some of the companies provided good guidance for FY 27.

Disc: No buy/sale recommendation. This is for educational purpose only

[Sameer Kumar @kumar_same65576]

#MAXVOLT